2024 World Conference on Lung Cancer (WCLC) - Posters-P2.10B.04 Paclitaxel Liposome Combined with Immunotherapy in the First-Line Treatment of Advanced NSCLC: A Multicenter Real-World Study

P2.10B.04 Paclitaxel Liposome Combined with Immunotherapy in the First-Line Treatment of Advanced NSCLC: A Multicenter Real-World Study

Back to course

Pdf Summary

The study focuses on the real-world effectiveness and safety of a first-line treatment combining paclitaxel liposome-based chemotherapy and immunotherapy for advanced non-small cell lung cancer (NSCLC) in Chinese patients. Conducted across nine Chinese hospitals between April 2020 and November 2023, the study evaluated 200 patients, 94% of whom were male, with a median age of 66 years. A significant number of cases, 81.5%, were diagnosed as squamous cell carcinoma.<br /><br />Paclitaxel liposome is a formulation that reduces the risk of drug-induced hypersensitivity by encapsulating paclitaxel with liposomes, removing the need for polyethoxylated castor oil. The study is part of the "Efficacy and Safety of Immunotherapy in NSCLC Patients" project, examining outcomes such as progression-free survival (PFS) and objective response rate (ORR). <br /><br />The median number of treatment cycles for paclitaxel liposome was four, often combined with various immunotherapy agents like tislelizumab, pembrolizumab, and sintilimab, alongside a high usage of carboplatin (92.5%). Patients showed a median PFS of 11.4 months and a 1-year PFS rate of 44%. Multivariate analysis highlighted treatment cycle numbers as a significant factor influencing PFS, with three cycles showing a better outcome.<br /><br />The effectiveness evaluation revealed an ORR of 59.1% and a disease control rate (DCR) of 90.9%, with 11 patients achieving complete response. Side effects occurred in 59% of patients, primarily bone marrow suppression, gastrointestinal reactions, and liver function abnormalities, with serious adverse events in 16.5% of cases.<br /><br />In conclusion, this treatment combination demonstrated substantial effectiveness and safety for advanced NSCLC, supporting its viability as a real-world treatment option. The study highlights the need for further research and is ongoing to refine its findings.

Asset Subtitle

Liyan Jiang

Meta Tag

Speaker Liyan Jiang

Topic Metastatic NSCLC – Cytotoxic Therapy

Keywords

NSCLC

paclitaxel liposome

immunotherapy

Chinese patients

squamous cell carcinoma

progression-free survival

objective response rate

treatment cycles

adverse events

real-world effectiveness